William T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical Officer
Prominent heart failure cardiologist Dr. William Abraham to play pivotal role in the advancement of the Carillon Mitral Contour System® to heart failure patients with FMR.
Cardiac Dimensions®, a leader in transcatheter therapies for heart failure, announced today the appointment of William T. Abraham, MD, as Chief Medical Officer. A globally recognized expert in heart failure and device-based therapies, Dr. Abraham will help lead the company’s clinical and regulatory strategies as it advances toward U.S. regulatory approval and continues to expand European commercial sales of the Carillon Mitral Contour System®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903095354/en/
Dr. William T. Abraham, Chief Medical Officer at Cardiac Dimensions
Dr. Abraham most recently served as the Chief Medical Officer at V-Wave Ltd., where he led the U.S. pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson. Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University, where he was the Director of the Division of Cardiovascular Medicine for more than 15 years, and has published over 650 peer-reviewed papers. He is internationally known for his leadership in advancing heart failure treatments, including cardiac resynchronization therapy, remote hemodynamic monitoring, and transcatheter valve repair. Dr. Abraham has also served as national or global principal investigator on more than 50 multicenter trials, including important trials within the mitral valve space.
“We are delighted to welcome Dr. Abraham to the Cardiac Dimensions leadership team,” said Rick Wypych, President and CEO of Cardiac Dimensions. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this much-needed therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal U.S. landmark study – The EMPOWER Trial.”
“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” said Dr. Abraham. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favorable atrial and ventricular remodeling, symptom improvement, and a excellent safety profile – even in patients with proportionate MR who are often excluded from other therapies.”
The Carillon Mitral Contour System has received CE Mark and is available for sale in Europe and other countries that recognize CE Mark.
About the CarillonMitral Contour System®
The Carillon Mitral Contour System is a minimally invasive device designed to treat heart failure patients with functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. It is commercially available in Europe, as well as other countries, and is currently being studied in the U.S. pivotal EMPOWER Trial.
About the EMPOWER Trial
The EMPOWER Trial is a prospective, randomized, sham-controlled pivotal study evaluating the safety and effectiveness of the Carillon Mitral Contour System® in heart failure patients with mild to severe functional mitral regurgitation. Designed to enroll up to 300 patients across leading U.S. and international centers, the trial aims to support FDA approval by demonstrating the Carillon therapy’s potential to improve symptoms, cardiac structure, and long-term outcomes in a broad heart failure population.
About Cardiac Dimensions®
Cardiac Dimensions is committed to addressing the rapidly growing patient population suffering from heart failure with functional mitral regurgitation. With decades of clinical experience and thousands of patients treated worldwide, the company’s Carillon device is uniquely positioned as a durable therapy designed to treat early and late-stage patients, improve symptoms and reverse disease progression. Learn more at www.cardiacdimensions.com.
CAUTION: In the United States, the Carillon System is an investigational device, limited by federal law to investigational use.
Cardiac Dimensions, Carillon, and Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions.
© 2025 Cardiac Dimensions. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903095354/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Named a Leader in IoT Security Solutions, Q3 2025 Evaluation3.9.2025 15:58:00 CEST | Press release
Recognition follows Armis being named a Leader in Unified Vulnerability Management Solutions evaluation Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide exposure management that goes beyond IoT and OT devices. Its innovation investments and acquisitions support this goal. Its roadmap aligns with customer priorities while anticipating future needs to ensure the platform evolves alongside its clients. This forward-looking strategy fosters successful adoption and helps customers deploy the Centrix platform successfully.” “We’re proud to once again be re
Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval3.9.2025 15:46:00 CEST | Press release
Clinical performance and strong physician demand drive swift uptake and global approval of next-generation access technology Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903530140/en/ “In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” stated Dr. Erez Nossek, a neurosurgeon at NYU Langone in New York, NY. “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.” As the first
Ondo Finance and Alpaca Collaborate to Tokenize US Stocks and ETFs3.9.2025 15:30:00 CEST | Press release
Bridging traditional finance and on-chain markets, increasing access to high-quality assets Today, Ondo Finance, a leader in blockchain-based financial innovation and tokenized real-world assets, announced the launch of Ondo Global Markets, their platform for tokenized US stocks and ETFs. The platform is powered by a strategic integration with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API for stocks, ETFs, and options trading, as well as crypto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903244835/en/ Ondo Finance and Alpaca collaborate to tokenize US stocks and ETFs; bridging traditional finance and on-chain markets, increasing access to high-quality assets. According to a McKinsey report, the tokenized market capitalization could reach around $2 trillion by 2030 across a variety of asset classes. This expected rise in market demand for tokenized assets, like US stocks and ETFs, comes as glob
TON Strategy Company Approves $250 Million Stock Repurchase Program After Ticker Change3.9.2025 15:20:00 CEST | Press release
Open-ended stock repurchase program unanimously approved by the board Aims to create shareholder value by growing Net Asset Value per Share (NAV/share), including in times of heightened volatility TON Strategy Company (formerly Verb Technology Company Inc.) (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that its Board of Directors has unanimously approved a stock repurchase program authorizing the Company to repurchase up to $250 million of its common stock. Under the program, repurchases may be made from time to time in open market transactions or through other means in accordance with applicable securities laws. The timing, number of shares of common stock repurchased, and price will depend on a variety of factors including liquidity, market conditions, share price, and other considerations. The program does not obligate the Company to acquire any specific number of shares of the Company’s common stock. "We are co
Matica Fintec Strengthens Global Banking and Payment Ecosystem With Acquisition of Panini3.9.2025 15:15:00 CEST | Press release
Matica Fintec S.p.A., a world-leading manufacturer and provider of technology solutions for Financial and Government Institutions, has announced the acquisition of Panini S.p.A., a global leader in check scanning and document digitization technologies previously owned by SETA Holding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903411079/en/ Matica Fintec S.p.A., has announced the acquisition of Panini S.p.A., a global leader in check scanning and document digitization technologies previously owned by SETA Holding. The acquisition unites two trusted industry players with deep expertise in secure financial transactions, enhancing Matica Fintec’s banking‑infrastructure capabilities and positioning the company for accelerated growth in its core markets. Moreover, Matica’s recent regional investments – including the manufacturing plant in South Carolina and Minnesota software center – will be a precious contribution to Pan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom